PRESS RELEASE published on 05/17/2023 at 12:30, 2 years 10 months ago Immunic Announces That Vidofludimus Calcium Acts as Potent Nurr1 Activator, Reinforcing Neuroprotective Potential in Multiple Sclerosis
PRESS RELEASE published on 05/06/2023 at 12:30, 2 years 10 months ago Immunic Presents Clinical and Preclinical Data for IMU-856 at Digestive Disease Week 2023, Including Its Molecular Mode of Action
PRESS RELEASE published on 05/04/2023 at 12:30, 2 years 10 months ago Immunic Reports Positive Results From Phase 1b Clinical Trial of IMU-856 in Celiac Disease, Providing Clinical Proof-of-Concept for New Therapeutic Approach to Gastrointestinal Disorders
PRESS RELEASE published on 04/27/2023 at 12:30, 2 years 10 months ago Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Richard Rudick, M.D.
PRESS RELEASE published on 04/26/2023 at 12:30, 2 years 10 months ago Immunic to Participate in Investor and Scientific Conferences in May
PRESS RELEASE published on 04/05/2023 at 12:30, 2 years 11 months ago Immunic Reports Positive Data from Maintenance Phase of Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Moderate-to-Severe Ulcerative Colitis
PRESS RELEASE published on 03/02/2023 at 12:30, 3 years ago Immunic to Participate in Investor and Scientific Conferences in March
PRESS RELEASE published on 02/22/2023 at 12:30, 3 years 1 month ago Immunic Presents Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis at ACTRIMS Forum 2023
PRESS RELEASE published on 02/09/2023 at 12:30, 3 years 1 month ago Immunic to Host Virtual Celiac Disease R&D Day to Highlight Current Pathways for Drug Development and Unmet Medical Need
PRESS RELEASE published on 01/25/2023 at 12:30, 3 years 1 month ago Immunic to Participate in Scientific and Investor Conferences in February
Published on 03/23/2026 at 08:00, 23 minutes ago ABRIDGED, PRELIMINARY AND UNAUDITED QUARTERLY AND FULL YEAR RESULTS AND DETAILS OF MANAGEMENT CONFERENCE Call for the Fourth Quarter and Full Year Ended December 31, 2025 ("The Quarter" or "Q4 2025" and "FY 2025" Respectively)
Published on 03/23/2026 at 02:00, 6 hours 23 minutes ago FutureGen Industries Announces Open Market Investments
Published on 03/23/2026 at 08:00, 23 minutes ago Zentra Group plc: Unaudited interim report for the six months ended 31 December 2025
Published on 03/23/2026 at 08:00, 23 minutes ago Notification of the Greenshoe-Option and Stabilization Measures in accordance with Art. 5 (4)(b), (5) and (6) of Reg. (EU) 596/2014 and Art. 8 (f) and Art. 6 (3) Comm. Delegated Reg. (EU) 2016/1052
Published on 03/23/2026 at 07:46, 37 minutes ago Delivery Hero to sell Taiwan food delivery operations to Grab for USD 600 million
Published on 03/23/2026 at 07:30, 53 minutes ago Nordex Group receives new order from Serbia for 70 MW
Published on 03/20/2026 at 19:00, 2 days 13 hours ago AXA - Conditions for availability or consultation of information relating to AXA’s Shareholders’ Meeting of April 30, 2026
Published on 03/20/2026 at 18:15, 2 days 14 hours ago Publication of AXA’s 2025 Universal Registration Document
Published on 03/20/2026 at 16:57, 2 days 15 hours ago Number of shares and voting rights - February 2026 (In French only)
Published on 03/19/2026 at 18:00, 3 days 14 hours ago Filing of the 2025 Universal Registration Document
